(Q37262966)

19 August 2017

1 reference

title

Metformin therapy and clinical uses (English)

1 reference

19 August 2017

1 reference

John H B Scarpello

1

1 reference

PubMed ID

18777488

19 August 2017

Harry C S Howlett

series ordinal

2

1 reference

PubMed ID

18777488

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

Diabetes and Vascular Disease Research

19 August 2017

1 reference

19 August 2017

5

1 reference

19 August 2017

3

1 reference

19 August 2017

157-167

1 reference

Reducing insulin resistance with metformin: the evidence today

19 August 2017

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, pla

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Thiazolidinediones for initial treatment of type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Rosiglitazone RECORD study: glucose control outcomes at 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Comparison of tolbutamide and metformin in elderly diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Diabetic macrovascular disease: the glucose paradox?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Complex causes of fatal myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Differential effects of metformin on bile salt absorption from the jejunum and ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

A risk-benefit assessment of metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin and lactic acidosis in diabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Re-evaluation of a biguanide, metformin: mechanism of action and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Serum creatinine predicts mortality in patients with peripheral artery disease: influence of diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin treatment in NIDDM patients with mild renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Contraindications to the use of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Contraindications can damage your health--is metformin a case in point?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Managing anovulatory infertility and polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Non-alcoholic fatty liver disease and the metabolic syndrome: effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Nonalcoholic Steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Current perspectives on HIV-associated lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The AMP-activated protein kinase pathway--new players upstream and downstream.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

Impaired fasting glucose and impaired glucose tolerance: implications for care

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2008.027

21 January 2018

Identifiers

DOI

10.3132/DVDR.2008.027

1 reference

19 August 2017

1 reference

PubMed ID

18777488